BiotechTube

mRNA-2752 + Durvalumab

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma

Conditions

Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma

Trial Timeline

Nov 27, 2018 → Aug 1, 2025

NCT ID
NCT03739931

About mRNA-2752 + Durvalumab

mRNA-2752 + Durvalumab is a phase 1 stage product being developed by AstraZeneca for Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03739931. Target conditions include Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma.

What happened to similar drugs?

1 of 1 similar drugs in Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma were approved

Approved (1) Terminated (0) Active (0)
✅Carbidopa/levodopa/entacaponeNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03739931Phase 1Completed

Competing Products

6 competing products in Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma

See all competitors
ProductCompanyStageHype Score
E3810 + E3810 + TeprenoneEisaiPhase 2/3
38
Rabeprazole + RabeprazoleEisaiPhase 2/3
38
LDE225 + BKM120NovartisPhase 1
29
Carbidopa/levodopa/entacaponeNovartisApproved
43
ETC-1002Esperion TherapeuticsPhase 1
23
AUTO CAR T cell therapyAutolus TherapeuticsPhase 2
32